These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 8282080)

  • 1. NGF and the treatment of Alzheimer's disease.
    Olson L
    Exp Neurol; 1993 Nov; 124(1):5-15. PubMed ID: 8282080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeated nicotine exposure in rats: effects on memory function, cholinergic markers and nerve growth factor.
    Hernandez CM; Terry AV
    Neuroscience; 2005; 130(4):997-1012. PubMed ID: 15652996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nerve growth factor pharmacology: application to the treatment of cholinergic neurodegeneration in Alzheimer's disease.
    Lapchak PA
    Exp Neurol; 1993 Nov; 124(1):16-20. PubMed ID: 8282073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nerve growth factor and Alzheimer's disease.
    Hefti F; Weiner WJ
    Ann Neurol; 1986 Sep; 20(3):275-81. PubMed ID: 3532929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of the neurotrophins and their receptors.
    Allen SJ; Dawbarn D
    Clin Sci (Lond); 2006 Feb; 110(2):175-91. PubMed ID: 16411894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles.
    Kurakhmaeva KB; Djindjikhashvili IA; Petrov VE; Balabanyan VU; Voronina TA; Trofimov SS; Kreuter J; Gelperina S; Begley D; Alyautdin RN
    J Drug Target; 2009 Sep; 17(8):564-74. PubMed ID: 19694610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.
    Eriksdotter-Jönhagen M; Linderoth B; Lind G; Aladellie L; Almkvist O; Andreasen N; Blennow K; Bogdanovic N; Jelic V; Kadir A; Nordberg A; Sundström E; Wahlund LO; Wall A; Wiberg M; Winblad B; Seiger A; Almqvist P; Wahlberg L
    Dement Geriatr Cogn Disord; 2012; 33(1):18-28. PubMed ID: 22377499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration.
    Tuszynski MH; Roberts J; Senut MC; U HS; Gage FH
    Gene Ther; 1996 Apr; 3(4):305-14. PubMed ID: 8732162
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for the planned clinical trials with nerve growth factor in Alzheimer's disease.
    Hefti F; Schneider LS
    Psychiatr Dev; 1989; 7(4):297-315. PubMed ID: 2487898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential use of neurotrophic agents in the treatment of neurodegenerative disorders.
    Tuszyński MH; Gage FH
    Acta Neurobiol Exp (Wars); 1990; 50(4-5):311-22. PubMed ID: 2130651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons; implications for Alzheimer's disease.
    Hefti F; Will B
    J Neural Transm Suppl; 1987; 24():309-15. PubMed ID: 2824691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct, complex effects of estrogens on basal forebrain cholinergic neurons.
    Bora SH; Liu Z; Kecojevic A; Merchenthaler I; Koliatsos VE
    Exp Neurol; 2005 Aug; 194(2):506-22. PubMed ID: 15893308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impairment of basal forebrain cholinergic neurons associated with aging and long-term loss of ovarian function.
    Gibbs RB
    Exp Neurol; 1998 Jun; 151(2):289-302. PubMed ID: 9628764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological basis of drug therapy of Alzheimer's disease.
    Sharma A; Parikh V; Singh M
    Indian J Exp Biol; 1997 Nov; 35(11):1146-55. PubMed ID: 9567741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CERE-110, an adeno-associated virus-based gene delivery vector expressing human nerve growth factor for the treatment of Alzheimer's disease.
    Mandel RJ
    Curr Opin Mol Ther; 2010 Apr; 12(2):240-7. PubMed ID: 20373268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGF and anti-transferrin receptor antibody conjugate: short and long-term effects on survival of cholinergic neurons in intraocular septal transplants.
    Granholm AC; Bäckman C; Bloom F; Ebendal T; Gerhardt GA; Hoffer B; Mackerlova L; Olson L; Söderström S; Walus LR
    J Pharmacol Exp Ther; 1994 Jan; 268(1):448-59. PubMed ID: 8301587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation--a pharmacological fMRI study.
    Goekoop R; Scheltens P; Barkhof F; Rombouts SA
    Brain; 2006 Jan; 129(Pt 1):141-57. PubMed ID: 16251213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.
    Eriksdotter Jönhagen M; Nordberg A; Amberla K; Bäckman L; Ebendal T; Meyerson B; Olson L; Seiger ; Shigeta M; Theodorsson E; Viitanen M; Winblad B; Wahlund LO
    Dement Geriatr Cogn Disord; 1998; 9(5):246-57. PubMed ID: 9701676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action.
    Brinton RD
    Ann N Y Acad Sci; 2005 Jun; 1052():57-74. PubMed ID: 16024751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.